Z ika virus (ZIKV), a single-stranded, positive-polarity RNA virus, belongs to the Flavivirus genus within the Flaviviridae family along with other clinically relevant arboviruses, such as yellow fever, Japanese encephalitis, West Nile, and dengue viruses (DENVs). 1 Although ZIKV is mostly transmitted from human to human through the bite of Aedes mosquitoes, 2 intrauterine, 3, 4 perinatal, 5 sexual, [6] [7] [8] [9] and probable transfusion transmissions (TTs) 10, 11 have been documented. In addition to high levels of viremia in plasma, ZIKV RNA and infectious ZIKV have been found in urine, [12] [13] [14] [15] [16] [17] breast milk, 5 saliva, 18 and semen. 9, 19 Considering the risk for severe clinical disease outcomes after maternal ZIKV infection, [20] [21] [22] [23] [24] monitoring and mitigation strategies are being deployed to alleviate the risk of transmission to pregnant women and conceiving couples. After the confirmation of increasing numbers of imported ZIKV infection cases in the United States, 25 including women delivering babies with ZIKV congenital syndrome after a history of travel to countries reporting active ZIKV transmission, 26 the US Centers for Disease Control and Prevention (CDC) released a travel advisory discouraging pregnant women from traveling to countries currently experiencing ZIKV outbreaks and new guidelines for the testing of pregnant women and their newborns living in or returning from epidemic areas. [27] [28] [29] [30] After reports of probable cases of transfusion and sexual transmission in late 2015 and early 2016, 10, 11 and in light of high rates of viremic blood donations reported during the French Polynesia outbreak in 2013 and 2014, 31 the US Food and Drug Administration (FDA) issued a "Guidance to Industry" in February 2016 precluding blood donations for 28 days after returning from countries with active ZIKV transmission or sexual contact with men returning from active transmission areas. 32 In active transmission areas, the February 2016 FDA guidance required blood to be imported from areas with no reported local transmission unless donations either were screened for ZIKV RNA by nucleic acid amplification technology (NAT) assays or were pathogen reduced using FDA-approved technologies for plasma and platelets. 32 Given the necessity of detecting donors in the preseroconversion viremic phase of infection, NAT-based, rather than serology-based, assays were recommended by the FDA, 32 the European Center for Disease Prevention and Control (ECDC), 33 and the World Health Organization (WHO) 34 for sensitive and specific detection of acute ZIKV infection, and particularly for donor screening. 35, 36 In response to this rapidly emerging threat, 36 government and academic laboratories and industry partners have developed ZIKV NAT assays. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) diagnostic tests developed by the CDC for the detection of ZIKV RNA (the Trioplex assay, which amplifies ZIKV, DENV and chikungunya virus [CHIKV] RNA, or a modified assay that detects only ZIKV) received emergency use authorization (EUA) from the FDA in March 2016. 37 This assay protocol and key reagents were distributed by the CDC to public health laboratories throughout the United States. Alternative versions of diagnostic RT-PCR and other NAT assays were developed and implemented in the United States and other countries, some of which subsequently received FDA EUA 37 or European Union CE (Conformit e Europ een)
marking. To facilitate blood donor screening, highthroughput and highly sensitive, ZIKV-specific NAT assays were developed for automated NAT testing systems manufactured by Roche Molecular Systems, Inc. (RMS) (the cobas Zika test for use on the cobas 6800/8800 Systems) and Hologic, Inc. (the Procleix ZIKV assay on the Panther system), which FDA has allowed the clinical studies to proceed under Investigational New Drug (IND) authorization for use to screen the blood supply in Puerto Rico and the 50 US states.
With limited access to clinical samples and virus isolates, and no international standards, the evaluation of relative sensitivities of ZIKV NAT assays was initially very challenging. After the FDA released its February 2016 guidance to safeguard the blood supply in areas with active transmission, 32 and with the impending mandate for ZIKV screening of blood donations in Puerto Rico and potentially US states, there was an urgent need to evaluate the performance (analytical sensitivity and specificity) of newly developed, investigational donor NAT screening assays to be implemented under IND authorization, relative to other diagnostic and blood screening assays developed by the CDC and commercial and national laboratories in the United States, France, French Polynesia, and Brazil. We took advantage of our access to clinical samples from Brazil and ZIKV virus isolates from collaborators in French Polynesia and Brazil to design and execute a blinded panel study to characterize the analytical performance of these assays. We focused on establishing the relative sensitivities of donor-screening NAT assays, which process approximately 500 mL plasma into each amplification relative to laboratory-developed, diagnostic PCR assays, which generally process less than 50 mL of plasmaderived RNA into PCR reactions; and subsequently developed modifications of PCR assays to enhance sensitivity with increased sample input volume. Using well characterized virus stocks and clinical samples with estimated RNA copy numbers, serially diluted samples were created and compiled into blinded panels, which were made available to 11 Polynesia ZIKV-positive plasma sample collected  during the Zika outbreak in 2013 (PF13/251013-18) 38,39 was cultured to generate an isolate and was expanded in vitro in Vero cells. A French Polynesia isolate supernatant was collected and stored at 2808C and was shared with the BSRI for further expansion to high titer in Vero cells, followed by aliquoting, and storage at 2808C (Fig. 1) . 10, 11, 32, 33, [40] [41] [42] [43] [44] [45] Plasma was acquired from a Brazilian blood donation during the Zika outbreak in 2015 that was implicated in the first reported cases of ZIKV TT. 10 The donation sample was identified as ZIKV RNA-positive after the donor reported symptoms several days postdonation; a recipient of a cellular blood component derived from this donation was tested retrospectively and determined to have acquired ZIKV from the transfusion based on the development of ZIKV viremia posttransfusion. The ZIKV RNA-positive plasma component from the implicated donation was aliquoted and retained in a repository at 2808C in Brazil until shipment on dry ice to BSRI for panel construction (Fig. 1 ).
MATERIALS AND METHODS

Source and characterization of analytical standards
A French
The two virus strains used in the panel had been extensively characterized by sequencing. 39, 46 Both viral stock of the French Polynesia ZIKV isolate and ZIKVcontaminated Brazilian plasma were quantified at BSRI for ZIKV RNA viral load (VL) by real time RT-PCR and for infectious particle titer in plaque-forming units (PFUs) by plaque assay on Vero cells. The RNA copy number of the French Polynesia ZIKV isolate was calculated from serial dilution, real-time RT-PCR data using a computational method based on maximum-likelihood estimation for copy number and assay sensitivity estimation. The ZIKV RNA endpoint was first determined based on 10-fold dilutions of the viral stock in plasma. Subsequently, eight 3-fold dilutions around the endpoint were prepared by diluting in plasma. Twenty replicate RNA extractions were performed for each of the two highest and two lowest dilutions, whereas 40 replicate RNA extractions were performed for each of the four intermediate dilutions. RNA was reverse transcribed and amplified in quadruplicate wells using two-step, real-time RT-PCR, and the number of positive replicates was recorded for each dilution. Maximum-likelihood estimation was used to combine the Poisson distribution estimators for all dilutions and to generate a copy number estimate that optimally fit the overall serial dilution data. The RNA copy number of the Brazilian ZIKV RNA-positive plasma was calculated by one-step real-time RT-PCR compared with a standard curve of the quantified French Polynesia ZIKV isolate.
Construction of the analytical performance panel
A 25-member, blinded ZIKV analytical performance panel was constructed. 50 and LOD 95 , respectively). Table 1 summarizes the key characteristics of the assays evaluated in this study. The Appendix provides more detailed summaries of methods for each assay.
ZIKV NAT assays
Statistical methods
Probit regression was performed using copy numbers as the dependent variable and positive or negative readings as independent variables. The R (version 3. ; release of initial guidelines to mitigate the risk of ZIKV transmission by the ECDC, 33 the WHO, 47 and the FDA 32, 48 ; ongoing collaborations with blood screening companies; and implementations of IND NAT assays and FDA-approved pathogen-reduction technology. 49, 50 Results of replicate testing for all 17 individual assays on the decoded analytical performance panels are reported in Table 2 . Table 3 presents the decoded results with assays grouped into 10 categories based on similar methods and/or findings (LODs). The assays had good specificity based on no reported reactive results on replicate analysis of the three negative control samples (except for one false-positive result with one of the assays performed at ILM), whereas the sensitivity of the assays varied by one to three logs based on comparisons of the percentage reactivity on serial dilutions and probit analyses to derive LOD 50 and LOD 95 . Thermo Fisher 7300 RT * The derived plasma input is a calculated parameter that represents the equivalent volume of plasma subjected to amplification: the volume of plasma from which RNA is extracted, multiplied by the proportion of the eluate used for amplification (plasma extraction volume 3
RNA input volume /elution volume).
N/A 5 not applicable. 
Comparison of donor-screening NAT assays with standard-input RT-PCR assays
The analytical performance was compared between the RMS cobas Zika and Hologic, Inc. Procleix ZIKV blood donor-screening NAT assays and with various versions of RT-PCR diagnostic assays developed by the CDC, FDA, and other laboratories. The RMS and Hologic blood donor-screening NAT assays, which extract nucleic acid from 850 mL and 500 mL of plasma, respectively, were comparable in sensitivity, with 100% detection of dilutions of both standards at levels from 10 to 40 estimated copies/ mL. Given the comparable performance of these donorscreening NAT assays based on the percentage reactivity on serial dilutions, their results were combined to allow for a more accurate assessment of These high-input donor-screening NAT assays were approximately 10-fold to 100-fold more sensitive than standard input diagnostic RT-PCR assays. These assays extract from 100 to 200 mL of plasma and process 12 to 42 mL of plasma-derived RNA per amplification ("Derived plasma input" in Table 1 ). We combined results from the CDC-PR LI assays; from the BSRI and UC Davis laboratories, which were performing similar versions of the CDC LI assays; and from the two Brazil PCR assays to compare the sensitivities relative to commercial NAT, FDA, EFS, and ILM assays (Table 3 , Fig. 2) . Combining results of similar assays provided more robust estimates for LODs: LOD 95 ranged from 107 to 6343 copies/mL, and LOD 50 ranged from 20 to 523 copies/mL for the diluted Brazil plasma panel; serially diluted French Polynesia isolate supernatant was detected at similar sensitivities, with LOD 95 ranging from 135 to 4918 copies/mL and LOD 50 ranging from 25 to 321 copies/mL. These findings confirmed the significantly better sensitivity of the commercial donor-screening NAT assays than other laboratory-developed tests and diagnostic PCR assays as well as PCR assays used to screen blood donors in French Polynesia and Brazil.
Enhanced-input assays increased sensitivity
The Trioplex assay was performed with both low inputs (LI) of plasma, as specified in the original EUA, and subsequently with increased or high inputs (HI) of plasma by the CDC laboratory in Puerto Rico. Compared with the original EUA input results from the US CDC laboratory in Puerto Rico, as well as results generated with the CDC protocol at the BSRI and UC Davis laboratories, increasing the sample extraction volume to 1.0 mL and amplification to 100 mL equivalent of plasma resulted in approximately 30-fold increased sensitivity for ZIKV RNA detection by the Trioplex HI assay. The CDC laboratory in Fort Collins also performed an enhanced sample extraction (300 mL vs. 100 mL) and increased RNA input (amplified 67 mL vs. 5 mL equivalent of plasma) and demonstrated a greater than 10-fold enhanced sensitivity of an HI assay relative to an LI assay. These results demonstrate that sensitivity is a function of sample input and can be improved with such assay modifications.
DISCUSSION
The rapidly expanding evidence for the severity of neurological complications associated with ZIKV infection, high rates of infection in travelers returning to the United States, and risk of autochthonous outbreaks in Puerto Rico and US states led to the urgency with which measures had to be taken to protect the US blood supply in early 2016. 32, 48 Implementation of a ban on the collection of blood in areas with active transmission without appropriate screening methods, which briefly occurred in Puerto Rico in March 2016 with funding for purchase and transport of blood from the continental United States by the federal government, established an urgent need for the development and implementation of sensitive, specific, and high-throughput donor-screening NAT assays to prevent ongoing disruptions of the blood system in the face of an evolving epidemic. In March 2016, BSRI and Creative Testing Solutions, which tests approximately 90% of the blood collected in Puerto Rico and Florida, actively considered implementing the CDC ZIKV PCR assay developed by the Puerto Rico CDC branch. However, concerns were raised over the sensitivity of the assay, such that implementation of the test as a donor-screening assay would likely not be sufficient to release locally collected, ZIKV PCR-negative blood for transfusion without additional recipient informed consent that included the option of providing recipients (and particularly pregnant women) with blood components imported from ZIKV low-risk regions of the United States. These concerns, and the expected availability of ZIKV assays from the major blood-screening NAT assay manufacturers, led to the development and execution of this study.
The results of this study suggest that the investigational donor-screening ZIKV NAT assays from RMS and Hologic had high and similar sensitivities for the detection of ZIKV RNA, with LOD 50 values calculated from the combined results of less than 5 copies/mL and LOD 95 of less than 20 copies/mL. The results of this study demonstrate that the ZIKV NAT assays from RMS and Hologic had analytical sensitivities similar to those of the NAT assays that target other TT viral infections, which are currently FDA-licensed and routinely used to screen the US and global blood supplies for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and West Nile virus. In addition, the analytical sensitivities of the investigational donor-screening NAT assays from RMS and Hologic are substantially higher than those of original CDC EUA Trioplex and the other laboratory-developed and diagnostic ZIKV PCR assays evaluated in this study, as well as assays that have been used in France, French Polynesia, and Brazil for donor-screening during ZIKV outbreaks. The differential sensitivities between assays correlated with and likely are primarily attributable to the volumes of plasma extracted and of eluted RNA that is amplified by different assays, so increasing sample input per assay may enhance sensitivities of diagnostic assays, as demonstrated by the relative sensitivities of LI and HI assays performed at the two participating CDC laboratories. The importance of differential sensitivities of assays on clinical diagnosis and and 95% confidence intervals (dashed lines) were used to estimate LOD 50 , LOD 95 , and the confidence intervals presented in Table 3 . . 48 The results of early screening indicate excellent specificity of both assays and detection of low but significant numbers of ZIKV-infected donors, both due to travel-acquired and autochthonous infections. 51, 52 This study has several limitations. First, due to limited volumes of panel members (1-mL aliquots were provided to most laboratories, except for the donor-screening NAT assay manufacturers, each of which was provided with three 1-mL aliquots), the number of replicate tests of diluted panel members performed using each assay was relatively small (range, 2-12), precluding precise estimation of LODs (which usually requires more than 25 replicates testing of each dilution). In particular, this study was not designed to rigorously compare the analytical sensitivities of the RMS and Hologic NAT assays due to the limited availability of dilutions of the study panels. Second, the quantitation of VLs in copies and PFUs/mL in the viral stocks and of serial dilutions in the panels is not precise and should be considered only estimates, although we believe conclusions on the relative sensitivities of different assays are reliable. Third, there was an amendment to the CDC ZIKV PCR EUA protocol in August 2016 that included recommendations to extract and test larger volumes of serum and to add procedures for Trioplex testing of whole blood in addition to urine and serum, which were the only sample types in the original EUA protocol. These changes should significantly improve the diagnostic sensitivity of that assay. Moreover, FDA has also authorized a number of other ZIKV NAT assays under EUA, including diagnostic tests from RMS and Hologic; it is likely that many of these assays have enhanced analytical sensitivities relative to the assays evaluated in this study.
In conclusion, the findings of this study suggest that the investigational ZIKV NAT assays for blood donor screening have excellent sensitivities similar to the sensitivities of the assays currently used to screen for established TT viruses. The donor-screening NAT assays from RMS and Hologic appear to be substantially more sensitive than most other laboratory-developed and diagnostic ZIKV RT-PCR assays evaluated in this study. Enhancing sensitivities of laboratory-developed and diagnostic assays may be achievable by increasing sample input or testing alternative sample types. Rapid implementation of blood donor NAT screening for ZIKV in Puerto Rico and US states and in several other countries represents a major accomplishment of many involved parties to assure blood safety during the expanding ZIKV pandemic.
APPENDIX
DETAILED ASSAY METHODS Roche Molecular Systems, Inc
The cobas Zika test for use on the cobas 6800/8800 Systems is a qualitative PCR test for the detection of ZIKV RNA in plasma specimens from individual human donors. The test includes assay-specific reagents and an external positive control, and it also shares cobas omni reagents and the negative control with other tests performed on the cobas 6800/8800 Systems. The cobas 6800/8800 Systems provide fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection.
During extraction of 850 mL of plasma, nucleic acids from the sample are processed simultaneously with added, armored RNA internal control (IC), which serves as the sample preparation and amplification/ detection process control. Viral nucleic acids are released by the addition of proteinase and lysis reagent and bind with IC RNA to magnetic glass particles. Unbound substances and impurities, such as denatured proteins, cellular debris, and potential PCR inhibitors, are removed by subsequent wash steps. Purified nucleic acids are eluted from the glass particles, and eluate is added to PCR master mix.
The cobas Zika master mix contains primers and detection probes specific for ZIKV selected from highly conserved regions of the viral genome, and it also contains oligonucleotides to amplify and separately detect the IC. A thermostable DNA polymerase is used for reverse-transcription and amplification. The master mix includes AmpErase enzyme (uracil-N-glycosylase) and deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any potentially contaminating amplicons from previous PCR runs are destroyed by AmpErase and rendered nondetectable. The specific ZIKV and IC detection probes are labeled with unique fluorescent dyes, allowing simultaneous detection and discrimination of the amplified Zika target and the IC for each sample. Automated data analysis is performed by the cobas 6800/8800 software, which assigns a test result for each test as nonreactive, reactive, or invalid.
Hologic, Inc
The Procleix ZIKV assay, developed in partnership with Grifols Diagnostic Solutions, is a qualitative in vitro assay to detect Zika RNA on the fully automated Panther system. The same assay, marketed as the Aptima ZIKV assay by Hologic, was subjected to additional verification and validation studies and was granted EUA status from the FDA for use as a diagnostic NAT. The Procleix and Aptima assays are based on the same technology as other Procleix assays, which involve three main steps: sample preparation using magnetic-based target capture, RNA amplification by transcription-mediated amplification (TMA), and detection of the amplification products by the hybridization protection assay (HPA) using chemiluminescent probes. To mitigate the risk of false negative results, the assay targets 2 separate viral target regions of the ZIKV genome and includes an internal control to validate each reaction. The assay uses 0.5mL input volume and all reaction steps occur in one tube with an IC incorporated. The IC is added into samples via the target capture reagent, to monitor target capture, amplification, and detection, as well as operator or instrument error. The analyte and IC probes produce chemiluminescent signals with different light emission kinetics that are distinguishable from one another. Results are expressed in relative light units (RLU) values and signal-to-cutoff (S/CO) values. A floating cutoff value is obtained with calibrators included in each run. A sample is considered "Reactive" if the analyte S/CO is greater than or equal to 1.0. A sample is considered "Nonreactive" if the analyte S/CO is less than 1.0 and the internal control signal is greater than the internal control cutoff. The sample result is considered "Invalid" if the internal control signal is greater than the set maximum, or both the analyte S/CO is less than 1.0 and the internal control signal is below the internal control cutoff. The sample with invalid result must be retested.
CDC Puerto Rico
CDC Trioplex RT-PCR Assay was run in three modalities: Multiplex Low Input (LI) (200 mL), Multiplex High Input (HI-1000 mL), and the Singleplex Zika modality (LI-mL). In the multiplex modalities, the CDC Trioplex assay is used for the simultaneous and qualitative detection and differentiation of DNGVs, CHIVs, and ZIKVs from a single sample. Extraction of 200 mL or 1 mL was performed on MagNA Pure 96 Total Nucleic Acid Isolation Kit (Roche). PCR reactions were amplified with 10 mL extracted RNA using the SuperScript III Platinum One-Step qRT-PCR Kit (Thermo Fisher) on 10 replcates using an Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher Scientific).
CDC Fort Collins
Two assays using two separate real-time primer/probe sets specific for the ZIKV 2007 strain (1087; 4481) were designed by using ZIKV 2007 nucleotide sequence data in the PrimerExpress software package (Applied Biosystems) and tested independently. 40 Primers were synthesized by Operon Biotechnologies with 5-FAM as the reporter dye for the probe. Standard input real-time assays were performed using the QuantiTect Probe RT-PCR Kit (Qiagen) with 5 ll of RNA extracted from 100 ll of plasma and eluted in 100 ll. High input RT-PCR assays were performed using the QuantiFast Pathogen RT-PCR 1 IC kit with 20 ll of RNA extracted from 300 ll of plasma eluted in 90 ll. Amplification was performed for both assays in the iCycler instrument (Bio-Rad) following the manufacturer's protocol.
BSRI
Viral RNA extraction: RNA was extracted from 140 mL of sample using the QIAamp Viral RNA Mini Kit (Qiagen) and eluted in 50 mL of water. Duplicate extractions were performed for each panel member. One-step real-time RT-PCR (CDC protocol): RNA was amplified in a 25-mL reaction mixture using the SuperScript III Platinum One-Step Quantitative RT-PCR System (Life Technologies Corporation) under the following conditions: 0.5 mL of the enzyme mixture, 12.5 mL of the 2x buffer, 0.25 mL of 100 mM each ZIKV 1086 (5 0 CCGCTGCCCAACACAAG 3 0 ) and ZIKV 1162c (5 0 CCACTAACGTTCTTTTGCAGACAT 3 0 ) primer, 0.15 mL of 25 mM ZIKV 1107 (5 0 AGCCTACCTTGACAAG-CAGTCAGACACTCAA 3 0 ) 6-FAM/ZEN/IBFQ probe, 6.35 mL of nuclease-free water, and 5 mL of extracted RNA. Duplicate amplifications were performed for each extracted sample. Amplification was performed in a LightCyler 480 real-time PCR instrument (Roche Diagnostics) in 96-well plates overlaid with 10 mL mineral oil per well using the following thermal profile: 30 minutes at 508C (combinational DNA [cDNA] synthesis), hold for 2 minutes at 958C, followed by 45 amplification cycles of 15 seconds at 958C and 1 minute at 608C. Data analysis was performed using the LightCycler 480 software. Two-step real-time RT-PCR (MTC protocol): RNA was reverse transcribed in a 48-mL reaction mixture containing: 4.8 mL of 10x solution A 1 B (1 M KCl; 0.1 M Tris, pH 8.3; 25 mM MgCl 2 ; 10% Tween-20; 10% NP-40), 0.5 mL of 100 mM deoxynucleotide triphosphates, 0.2 mL of 100 mM ZIKV 1162c primer, 1.2 mL of 40 U/mL RNase inhibitor, 1.2 mL of 50 U/mL MuLV reverse transcriptase, and 40 mL of extracted RNA. cDNA synthesis was performed for 30 minutes at 428C followed by reverse transcriptase inactivation for 10 minutes at 958C. cDNA was amplified in a 15-mL reaction mixture containing: 9.54 mL of PCR buffer, 0.1 mL of 100 mM deoxynucleotide triphosphates, 0.1 mL of 100 mM each ZIKV 1086 and ZIKV 1162c primers, 0.02 mL of 100 mM ZIKV 1107 probe, 0.14 mL of 5 U/mL FastStart Taq DNA polymerase, and 5 mL of cDNA. Duplicate amplifications were performed for each extracted sample. Amplification was performed in a LightCycler 480 realtime PCR instrument in 96-well plates overlaid with 10-mL mineral oil per well using the following thermal profile: 1 minute at 958C (DNA polymerase activation), followed by 45 amplification cycles of 30 seconds at 958C and 1 minute at 608C. Data analysis was performed using the LightCycler 480 software.
UC Davis
Each of 24 panel samples was divided into 4 aliquots of 140 mL and mixed with 560 mL of AVL buffer (Qiagen) for individual RNA extractions in parallel. This yielded a total of 96 samples, some of which were stored at 4 C for up to 1 week after the addition of AVL buffer before RNA was extracted. RNA was extracted from all samples using the QIAamp Viral RNA mini kit (Qiagen 52906) in accordance with the protocol provided and was then eluted in 60 mL of non-diethyl pyrocarbonate-treated water. After extraction, all RNA samples were stored at 280 C. Quantitative RT-PCR was performed with the Taqman Fast Virus One-Step Master Mix (Thermo 4444436), using the primers and probes published by Lanciotti et al. 40 All 96 samples were tested in triplicate using an Applied Biosystems ViiA 7 quantitative RT-PCR machine. A volume of 9.6 mL RNA was used in each sample. For results in which the cycle threshold (Ct) values did not match what was expected (e.g., loose triplicates), the multicomponent graph was analyzed visually using the Applied Biosystems software. False-positive values were identified by straight horizontal lines on the multicomponent graph, as opposed to a horizontal line with an upward curving tail at the very end (indicating amplification). Viral RNA levels were calculated in log copies by comparing the average of each samples' triplicate to the standard curve generated on each PCR plate.
FDA
RNA extraction from 140 mL of plasma was performed using the QIAamp Viral RNA mini kit with QIACube (Qiagen) and eluted in 60 mL. An extracted RNA volume of 5 mL was tested using Taqman Fast Virus One-Step Master Mix (Thermo Fisher) with primers and probe and was amplified on the ViiA 7 instrument (Applied Biosystems). The primer and probe sets used were as previously described. 40 
EFS
Individual NAT screening was performed on a semiautomated platform using a Microlab STARlet (Hamilton) for nucleic acid extraction and CFX96 (Bio-Rad Laboratories) automation for RT-PCR. Briefly, according to the manufacturer's instructions, nucleic acids were extracted in a final volume of 50 mL from 140 mL of sample using the NucleoSpin 96 Virus Extraction Kit (Macherey-Nagel GmbH & Company KG), and 10 mL of eluate was tested by RT-PCR using the RealStar Zika Virus RT-PCR Kit 1.1 (Altona Diagnostics GmbH). Each run was validated by positive and negative controls, and nucleic acid extraction for each sample was validated by an internal control.
ILM
RNA was extracted from 200 mL of plasma and eluted in 50 mL using the NucliSENS EasyMAG extraction system (bioM erieux), as previously reported.
12 ZIKV realtime RT-PCR using 5 mL input RNA was performed on a CFX BioRad real-time PCR analyzer using two realtime primers/probe amplification sets in two separate assays specific for ZIKV 40 with a Ct cutoff less than 38.5. Serial dilutions of an RNA synthetic transcript that covers the region targeted by the two primers/ probe sets were amplified to monitor sensitivity. Results were reported as positive and blood products were discarded if any of the amplification was positive.
Brazil
Fundação Pr o-Sangue. Extraction is performed on the MagNA pure Compact (RMS) with the large-volume kit of 250 mL of samples eluted in 60 mL. Real-time PCR is performed in the Step-One Plus machine from Applied Biosciences (now Thermo Fisher Scientific) or on the Light Cycler 480 from RMS. RNA input is 10 mL in a final volume of 20 mL, including 5 mL 4x Taqman fast virus mix, 5 mL water, 0.6 mL/0.4 mL 40x mix primers, and probe. Before extraction, samples were spiked with a diluted preparation of the Salk polio vaccine (used as the internal control), and run duplex Zika-polio virus PCR, with both sets using 500-nM primers with a 250-nM probe. Zika probe was labeled with FAM, and polio was labeled with VIC (or HEX). Primer/probe sets were used as previously described. 40 Laborat orio Richet. RNA was extracted from 140 lL of samples using the QIAamp Viral RNA Mini Kit (Qiagen), and RNA was eluted with 60 lL of RNase-free water. For control of the extraction process, 4 mL of an internal control was added in each sample in lysis buffer and, the Ct was considered valid between 25 and 31. For the ZIKV RT PCR, the Bio Gene ZIKV PCR kit (Bioclin) was used with the RT primers and probes and master mix provided in the kit. The probes were designed with 5-FAM as the reporter dye for the target and with Vic for internal control. Five microliters of extracted RNA sample was used for a total reaction volume of 20 lL. All real-time assays were performed using amplification in the 7300 RT instrument (Thermo Fisher Scientific) following the manufacturer's protocol.
